VIA
MDNA

Vident Investment Advisory’s Medicenna Therapeutics Corp. Common Shares MDNA Stock Holding History

Vident Investment Advisory’s Portfolio MDNA Stock Details MDNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-65,878
Closed -$110K – 1355
2021
Q4 		$110K Buy
65,878
+2,998
+5% +$6.22K ﹤0.01% 1175
2021
Q3 		$172K Buy
+62,880
New +$156K 0.01% 1099

Other funds holding MDNA

ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
WVP
Worth Venture Partners Fort Lee, New Jersey $31.6M AUM 28.5% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return
SPC
Sigma Planning Corp Ann Arbor, Michigan $3.6B AUM 24.57% 1-Year Est. Return
ACM
ACT Capital Management Wayne, Pennsylvania $127M AUM
LBA
Letko, Brosseau & Associates Montreal, Quebec, Canada $6.2B AUM 38.92% 1-Year Est. Return
IIM
Intact Investment Management Montreal, Quebec, Canada $3.52B AUM 37.29% 1-Year Est. Return
TAM
Tocqueville Asset Management New York $6.74B AUM 32.29% 1-Year Est. Return
MCWS
McKinley Carter Wealth Services Wheeling, West Virginia $1.94B AUM 20.7% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Vident Investment Advisory's MDNA Position: Q1 2022 in Review

Vident Investment Advisory sold out of Medicenna Therapeutics Corp. Common Shares (MDNA) in Q1 2022, closing a stake of 65,878 shares — an estimated $110K sold.

Vident Investment Advisory first reported a position in MDNA in Q3 2021 and held it in 2 quarters. The position peaked at $172K in Q3 2021. 20 funds tracked by Wall St. Rank hold MDNA as of Q1 2022.

  • Vident Investment Advisory reported no remaining Medicenna Therapeutics Corp. Common Shares position as of Q1 2022 after selling out during the quarter.
  • Vident Investment Advisory sold 65,878 Medicenna Therapeutics Corp. Common Shares shares in Q1 2022, an estimated $110K.
  • Vident Investment Advisory first reported a position in Medicenna Therapeutics Corp. Common Shares in Q3 2021 and held it in 2 quarters.
  • Vident Investment Advisory's Medicenna Therapeutics Corp. Common Shares position peaked at $172K in Q3 2021.
  • 20 funds tracked by Wall St. Rank held Medicenna Therapeutics Corp. Common Shares as of Q1 2022.

Based on Vident Investment Advisory's 13F filing for Q1 2022, filed 16 May 2022.